Home > Publications database > Gastric cancer: from biomarkers to functional precision medicine. > print

001     302158
005     20251208120018.0
024 7 _ |a 10.1016/j.molmed.2025.05.007
|2 doi
024 7 _ |a pmid:40555635
|2 pmid
024 7 _ |a 1471-4914
|2 ISSN
024 7 _ |a 1471-499X
|2 ISSN
024 7 _ |a altmetric:178324037
|2 altmetric
037 _ _ |a DKFZ-2025-01276
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Albrecht, Philipp
|0 P:(DE-He78)4e86fa59267a71d54ea7af1a2d9695ff
|b 0
|e First author
|u dkfz
245 _ _ |a Gastric cancer: from biomarkers to functional precision medicine.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765181153_2584395
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B440#LA:B440# / 2025 Dec;31(12):1089-1102
520 _ _ |a Gastric cancer (GC) remains a deadly disease because of late detection and limited treatment options at advanced stages. Treatment of patients with metastatic disease is based on chemotherapy, complemented by antibodies targeting HER2, VEGFR2, and more recently PD-1 or claudin 18.2. Further targets, such as FGFR2b, as well as novel drug classes including antibody-drug conjugates (ADCs) and bispecific antibodies, are promising developments in GC treatment. Despite the failure of several targeted agents, the landscape of GC therapy is evolving rapidly, facilitated by umbrella or platform precision medicine trials. The integration of next-generation sequencing and other omics techniques into molecular tumor boards, as well as functional drug testing on patient-derived models, might bring us closer to personalized oncology and ultimately improve patient survival.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a functional precision medicine
|2 Other
650 _ 7 |a gastroesophageal adenocarcinoma
|2 Other
650 _ 7 |a immunotherapy
|2 Other
650 _ 7 |a patient-derived organoids
|2 Other
650 _ 7 |a precision oncology
|2 Other
650 _ 7 |a targeted therapy
|2 Other
700 1 _ |a Karabati, Ekin
|0 P:(DE-He78)47c263f05a60d6be71229d9e4d82c79c
|b 1
|u dkfz
700 1 _ |a Ebert, Matthias P
|b 2
700 1 _ |a Betge, Johannes
|0 P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.molmed.2025.05.007
|g p. S1471491425001182
|0 PERI:(DE-600)2155736-6
|n 12
|p 1089-1102
|t Trends in molecular medicine
|v 31
|y 2025
|x 1471-4914
909 C O |o oai:inrepo02.dkfz.de:302158
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)4e86fa59267a71d54ea7af1a2d9695ff
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)47c263f05a60d6be71229d9e4d82c79c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a Local Funding
|0 PC:(DE-HGF)0001
|2 APC
915 p c |a DFG OA Publikationskosten
|0 PC:(DE-HGF)0002
|2 APC
915 p c |a DEAL: Elsevier 09/01/2023
|0 PC:(DE-HGF)0125
|2 APC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TRENDS MOL MED : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b TRENDS MOL MED : 2022
|d 2025-01-06
920 2 _ |0 I:(DE-He78)B440-20160331
|k B440
|l NWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle
|x 0
920 1 _ |0 I:(DE-He78)B440-20160331
|k B440
|l NWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 0 _ |0 I:(DE-He78)B440-20160331
|k B440
|l NWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B440-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21